Saturn1

Positive data to be presented at WCC VIII and AAO 2022 conferences in Chicago Tarsus recently submitted NDA to the FDA for TP-03 IRVINE, Calif., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose…

New Saturn-1 data demonstrated a strong patient responder rate with 95% of Demodex blepharitis patients treated with TP-03 achieving ≤0.5 mites per lash and 93% improving by at least one collarette grade Further Saturn-1 safety analysis…

Saturn-1 Phase 2b/3 trial met all primary and secondary endpoints, and demonstrated significant, clinically meaningful outcomes with no serious treatment-related adverse events and no treatment-related discontinuations, demonstrating the…

IRVINE, Calif., June 18, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply proven science and new technology to…